Monitor for any subsequent filings that may elaborate on the failed resolutions (8, 10, 11) and their implications for corporate governance or strategic direction. The lack of detail suggests no immediate trading catalyst.
Price Chart
Executive Summary
Biodexa Pharmaceuticals reported the results of its Annual General Meeting held June 30, 2026. Ordinary resolutions 1 through 7 passed with majorities ranging from 73% to 94%, while ordinary resolution 8 and special resolution 10 failed. Resolution 11, contingent on resolution 8, also failed. The filing does not disclose the specific subjects of the resolutions, making this a routine corporate governance update with no material financial or operational impact.
Key Facts
- Ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91%, and 94% respectively.
- Ordinary resolution 8 and special resolution 10 failed to pass.
- Resolution 11, contingent on resolution 8, also failed.
- The specific subjects of the resolutions were not disclosed in the filing.
Financial Impact
No financial impact disclosed; routine AGM results without material financial data.
Risk Factors
- Potential shareholder dissent if failed resolutions were material to governance or capital structure.
- Uncertainty around the nature of the failed resolutions could lead to speculation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004399 |
| Exhibit: exh_991.htm | 0001171843-26-004399 |
| Document: 0001171843-26-004399-index-headers.html | 0001171843-26-004399 |
| Document: 0001171843-26-004399-index.html | 0001171843-26-004399 |
| Document: 0001171843-26-004399.txt | 0001171843-26-004399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 6-K | $0.4849 | awaiting T+20 | — | $4.11 (+747.60%) |
Oct 8, 2026 18d ago | 6-K | $0.4602 | awaiting T+20 | — | $4.11 (+793.09%) |
Oct 1, 2026 26d ago | EFFECT | $0.6326 | awaiting T+20 | — | $4.11 (−549.70%) |
Sep 24, 2026 4w ago | F-1 | $0.6750 $0.4140 | ▲ +38.67% | ▲ +38.25% | $4.11 (−508.89%) |
Sep 15, 2026 6w ago | 6-K | $1.33 $0.3502 | ▼ −73.67% | ▼ −76.65% | $4.11 (+209.02%) |
Sep 11, 2026 6w ago | 6-K | $1.12 $0.3832 | ▲ +65.79% | ▲ +68.05% | $4.11 (−266.96%) |
Aug 4, 2026 12w ago | EFFECT | $11.92 $6.25 | ▲ +47.58% | ▲ +46.35% | $4.11 (+65.52%) |
Jun 30, 2026 16w ago | 6-K | $3.00 $1.45 | ▼ −51.83% | ▼ −49.65% | $4.11 (+37.00%) |
Jun 30, 2026 17w ago | 6-K | $2.91 $1.45 | ▲ +50.34% | ▲ +48.03% | $4.11 (−41.24%) |
Jun 17, 2026 18w ago | 6-K | $3.06 $2.13 | ▼ −30.39% | ▼ −30.93% | $4.11 (+34.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers